Neurocrine Wins FDA Approval For Genetic Disorder Drug

The approval of Neurocrine's newest drug, Crenessity, came roughly two weeks ahead of expectations. Crenessity, formerly crinecerfont, is treats congenital adrenal hyperplasia, or CAH, in adults and children as young as 4 years old.